Logo image of IPX

IPERIONX LTD - ADR (IPX) Stock Fundamental Analysis

NASDAQ:IPX - Nasdaq - US44916E1001 - ADR - Currency: USD

27.97  -1.32 (-4.51%)

Fundamental Rating

3

IPX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 151 industry peers in the Metals & Mining industry. The financial health of IPX is average, but there are quite some concerns on its profitability. While showing a medium growth rate, IPX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

IPX had negative earnings in the past year.
IPX had a negative operating cash flow in the past year.
In the past 5 years IPX always reported negative net income.
IPX had a negative operating cash flow in each of the past 5 years.
IPX Yearly Net Income VS EBIT VS OCF VS FCFIPX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

IPX has a Return On Assets of -39.40%. This is amonst the worse of the industry: IPX underperforms 86.71% of its industry peers.
Looking at the Return On Equity, with a value of -42.55%, IPX is doing worse than 81.12% of the companies in the same industry.
Industry RankSector Rank
ROA -39.4%
ROE -42.55%
ROIC N/A
ROA(3y)-111.03%
ROA(5y)-168.25%
ROE(3y)-139.15%
ROE(5y)-240.98%
ROIC(3y)N/A
ROIC(5y)N/A
IPX Yearly ROA, ROE, ROICIPX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600

1.3 Margins

IPX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IPX Yearly Profit, Operating, Gross MarginsIPX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -50K -100K -150K -200K -250K

More info and screens

6

2. Health

2.1 Basic Checks

IPX does not have a ROIC to compare to the WACC, probably because it is not profitable.
IPX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, IPX has more shares outstanding
The debt/assets ratio for IPX has been reduced compared to a year ago.
IPX Yearly Shares OutstandingIPX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
IPX Yearly Total Debt VS Total AssetsIPX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

IPX has an Altman-Z score of 123.59. This indicates that IPX is financially healthy and has little risk of bankruptcy at the moment.
IPX has a better Altman-Z score (123.59) than 97.20% of its industry peers.
A Debt/Equity ratio of 0.02 indicates that IPX is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.02, IPX is in the better half of the industry, outperforming 72.03% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 123.59
ROIC/WACCN/A
WACC10.63%
IPX Yearly LT Debt VS Equity VS FCFIPX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

IPX has a Current Ratio of 13.62. This indicates that IPX is financially healthy and has no problem in meeting its short term obligations.
IPX has a Current ratio of 13.62. This is amongst the best in the industry. IPX outperforms 92.31% of its industry peers.
IPX has a Quick Ratio of 13.61. This indicates that IPX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 13.61, IPX belongs to the best of the industry, outperforming 92.31% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 13.62
Quick Ratio 13.61
IPX Yearly Current Assets VS Current LiabilitesIPX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 3.42% over the past year.
The Revenue has grown by 10.43% in the past year. This is quite good.
IPX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 78.71% yearly.
EPS 1Y (TTM)3.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.98%
Revenue 1Y (TTM)10.43%
Revenue growth 3Y375.46%
Revenue growth 5Y78.71%
Sales Q2Q%13.26%

3.2 Future

The Earnings Per Share is expected to grow by 65.23% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y24.84%
EPS Next 2Y20.46%
EPS Next 3Y59.51%
EPS Next 5Y65.23%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IPX Yearly Revenue VS EstimatesIPX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 100M 200M 300M
IPX Yearly EPS VS EstimatesIPX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 1 2 3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

IPX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IPX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IPX Price Earnings VS Forward Price EarningsIPX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40 -60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IPX Per share dataIPX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as IPX's earnings are expected to grow with 59.51% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.46%
EPS Next 3Y59.51%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IPX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IPERIONX LTD - ADR

NASDAQ:IPX (2/21/2025, 8:00:02 PM)

27.97

-1.32 (-4.51%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryMetals & Mining
Earnings (Last)09-27 2024-09-27
Earnings (Next)03-18 2025-03-18
Inst Owners34.31%
Inst Owner Change59.61%
Ins Owners13.4%
Ins Owner ChangeN/A
Market Cap818.69M
Analysts80
Price Target25.79 (-7.79%)
Short Float %0.16%
Short Ratio0.62
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-14.43%
PT rev (3m)26.28%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-64.29%
EPS NY rev (3m)-42.29%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-44.13%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1499.35
P/FCF N/A
P/OCF N/A
P/B 15.95
P/tB 15.95
EV/EBITDA N/A
EPS(TTM)-0.77
EYN/A
EPS(NY)-0.45
Fwd EYN/A
FCF(TTM)-0.91
FCFYN/A
OCF(TTM)-0.64
OCFYN/A
SpS0.02
BVpS1.75
TBVpS1.75
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -39.4%
ROE -42.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-111.03%
ROA(5y)-168.25%
ROE(3y)-139.15%
ROE(5y)-240.98%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 1477.88%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.62
Quick Ratio 13.61
Altman-Z 123.59
F-Score4
WACC10.63%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)909.11%
Cap/Sales(5y)2910.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.98%
EPS Next Y24.84%
EPS Next 2Y20.46%
EPS Next 3Y59.51%
EPS Next 5Y65.23%
Revenue 1Y (TTM)10.43%
Revenue growth 3Y375.46%
Revenue growth 5Y78.71%
Sales Q2Q%13.26%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-23.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year73.33%
EBIT Next 3Y59.71%
EBIT Next 5Y69.61%
FCF growth 1Y-43.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-17.29%
OCF growth 3YN/A
OCF growth 5YN/A